Abstract Background Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is considered to be a nearly
Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a devastating prognosis and a median survival from the time of diagnosis of only 2-3 years (1). Although the disease is chronic in nature, one complication that has received little attention is an accelerated phase of the disease, namely acute exacerbation (AE) (2-6). It is a fulminant form of lung injury that leads to death in a period of a few weeks to a few months. AE of IPF has been defined as a condition with the following clinical characteristics: Under a previous or concurrent diagnosis of IPF, 1) exacerbation of dyspnea within 1 month, 2) newly developed diffuse bilateral ground-glass abnormality and/or consolidation superimposed on background reticular or honeycomb pattern consistent with the usual interstitial pneumonia pattern on highresolution computed tomography, 3) deterioration of hypoxemia more than 10 torr from the previous level at rest, and 4) absence of apparent lung infection, peumothorax, malignant tumor, pulmonary embolism or congestive heart failure (6). Recently, Collard et al (7) described the definition of AE in IPF as an acute, clinically significant deterioration in respiratory status of unidentified cause. This newly proposed diagnostic criteria requires endotracheal aspirate or bronchoalveolar lavage (BAL) to rule out respiratory infection or other identifiable etiologies as causes of the worsening condition (7).
AE is recognized to be a nearly fatal condition during the clinical course of IPF, as it is unresponsive to most of the conventional therapies such as corticosteroid (CS), and the patient eventually dies (2-6). The effectiveness of CS is thus limited, although CS has long been utilized for treating AE (2-7).
Previously, cyclosporin A (CsA) has been shown to be efficacious in the treatment of interstitial pneumonia (IP) associated with polymyositis and dermatomyositis (PM/DM) and other collagen vascular diseases that are refractory to CS therapy (8) (9) (10) (11) (12) (13) . Recent reports have also shown that CsA is efficacious in the treatment of AE of IPF (14, 15) 
Subjects and Methods
Disease assessments and definitions
Results
Patient backgrounds
The CsA-treated group comprised of 11 
CT scoring before and after AE
The characteristic HRCT features of exacerbated IPF were diffuse bilateral ground glass opacity superimposed on UIP patterns (3-6, 17, 18 
T a b l e 1 . P a t i e n t s B a c k g r o u n d s a t t h e T i me o f AE
Triggers of AE
Upper respiratory tract infection was the most common cause of AE in both groups (36% in the CsA-treated group and 55% in the non-CsA-treated group). Other causes were rapid dose reduction (>20 mg/month) of CS (9% in the nonCsA-treated group), surgical operation (AE developed at 6th postoperative days after surgical lobectomy for lung cancer) (9% in the CsA-treated group) and pleurodesis (18% in the CsA-treated group). No significant differences were noted between these two groups.
PaO2/FiO2
PaO2/FiO2 before (within 6 month) and after AE in the CsA-treated group were 290 ± 100 and 157 ± 100, respectively, and were 352 ± 62 and 195 ± 100 in the non-CsAtreated group, respectively. There were no significant differences in PaO2/FiO2 before and after AE between the CsAtreated and the non-CsA-treated groups ( Table 1) . (4-7, 19-21, 23) . Patients who died shortly after the onset of AE showed an acute phase of DAD, whereas those who survived the initial insult of AE but died of repeated AE afterward showed an organized phase of DAD (19) (20) (21) 23 T a b l e 2 . P r o g n o s i s a f t e r Ac u t e E x a c e r b a t i o n 
Treatment of IPF before AE
Pathological findings
The histopathological evaluation of lung specimens taken from patients who died of AE of IPF in both of the two groups presented a pattern of diffuse alveolar damage (DAD) such as the formation of hyaline membranes and alveolar type II cell hyperplasia. The UIP pattern was confirmed by the presence of patchy collagen fibrosis associated with scarring distributed in a peripheral and subpleural fashion, as well as honeycomb change. Evidence of superimposed DAD comprised areas of diffuse alveolar septal expansion and distortion by fibroblasts and myofibroblasts within the pale-staining matrix (acute phase of DAD). Proliferating spindle cells expanded and distorted alveolar septa with marked hyperplasia of pneumocytes, exudation of hyaline membranes, and squamous metaplasia of bronchiolar epithelium (organized phase of DAD)
F i g u r e 1 . S u r v i v a l r a t e . T h e p r o g n o s i s o f t h e Cs A-t r e a t e d g r o u p wa s s i g n i f i c a n t l y b e t t e r t h a n t h a t o f t h e g r o u p wi t h o u t Cs A t r e a t me n t i n a c u t e e x a c e r b a t i o n o f I P F .
Discussion
IPF is a slowly but relentlessly progressing disease (1-7).
The most common causes of death are respiratory failure and cor pulmonale generally resulting from advanced fibrotic lung disease (1) (2) (3) (4) (5) (6) (7) . Patients with IPF may also suffer from acute respiratory deterioration related to complications with a known cause such as pneumonia, pneumothorax, and pulmonary embolism (1) (2) (3) (4) (5) (6) (7) . However, a subset of IPF patients would experience an accelerated deterioration of the illness in the absence of any identifiable precipitating cause, namely, AE, which clinically resembles the acute respiratory distress syndrome (2) (3) (4) (5) (6) (7) (19) (20) (21) (22) (23) (24) (3-6, 17, 18) . Eventually, ground glass scores were significantly increased in a similar fashion after AE in both the CsA-treated and the non-CsA-treated groups.
Importantly, superimposed DAD is the characteristic histopathology of AE of IPF (3-6, 19, 23) . In this context, Rice and colleagues (19) (26) .
However, the effectiveness of CsA on IPF is controversial. Alton et al (27) 
